-+ 0.00%
-+ 0.00%
-+ 0.00%
Reviva Q2 FY26 net loss narrows to $2.4 million; cash climbs to $19.9 million as of June 30, 2026
Share
Listen to the news
Reviva Q2 FY26 net loss narrows to $2.4 million; cash climbs to $19.9 million as of June 30, 2026
  • Reviva reported a Q2 net loss of USD 2.4 million, narrowing from a USD 6.1 million loss a year earlier.
  • Loss per share improved to USD 0.19 from USD 2.40 in the prior-year quarter.
  • Cash and cash equivalents rose to USD 19.9 million at June 30 from USD 14.4 million at Dec. 31.
  • Filed a U.S. composition-of-matter patent application for a new brilaroxazine form, aiming to extend exclusivity through 2046.
  • Targets FDA feedback on using the new formulation in RECOVER-2 and an NDA in Q4 2026; RECOVER-2 enrollment planned 1H 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Reviva Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608121629PRIMZONEFULLFEED9809046) on August 12, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending